Prediction of malignancy and adverse outcome of solid pseudopapillary tumor of the pancreas

Table 1 Reported series (> 20 cases) of solid pseudopapillary tumor of the pancreas in the English literature

Ref.	Country	Centers	F/M	Age (yr)	Size (cm)	Malignant, n (%)	Follow up (mo)	R/M (n)	Alive (n)
Peng et al[17], 2006	China	Single	25/0	33 (11-65)	9.3 (2.5-25)	3 (12)	3-111	0	25
Yu et al[18], 2007	China	Single	25/1	25.2 (13-57)	7.5 (3.8-15)	9 (34.6)	66 (10-237)	2	24
Machado et al[19], 2008	Brazil	Single	27/7	23 (10-72)	7 (1.5-15)	13 (38.2)	84 (3-170)	2	33
Lee et al[20], 2008	South Korea	Multi	57/5	30 (8-63)	6.5 (1.5-14)	9 (14.5)	47.5 (5.1-240.4)	2	62
Matos et al[21], 2009	United States/Germany	Multi	20/1	33 (13-60)	5.5 (2.5-19.3)	3 (14.3)	55 (7-176)	0	21
Nguyen et al[22], 2011	Australia	Multi	30/4	33.3 (19.6-42.3)	6 (4.5-9)	9 (26.5)	70 (48-178)	2	32
Kim et al[23], 2011	South Korea	Single	98/16	36 (11-75)	4.2 (1.2-15)	26 (22.8)	57 (11-177)	4	114
Butte et al[24], 2011	United States	Single	38/7	38 (10-63)	4.9 (1.4-20)	9 (20)	44 (1-250)	5	381
Cai et al[25], 2013	China	Single	30/3	29.2 (12-59)	4.9 (2-15)	17 (51.5)	45 (4-118)	1	32
El Nakeeb et al[26], 2013	Egypt	Single	22/2	24.83 (12-52)	9.2 (3-25)	6 (25)	71.6 (1-180)	2	22
Raman et al[27], 2013	United States	Single	43/8	29.3 (12.2-74.8)	5.3 (1.7-11.1)	11 (21.6)	37 (0-122)	1	50
Serrano et al[28], 2014	Canada	Single	26/6	36 (13-64)	4.7 (1.5-14)	15 (46.9)	43 (3-207)	3	31
Suzuki et al[29], 2014	Japan	Single	29/5	37.1 (15-68)	4.3 (1-11)	3 (8.8)	67 (3-326)	0	34
Kim et al[30], 2014	South Korea	Single	85/21	36 (10-65)	4.5 (1-15)	17 (16)	56.9 (37-93.4)	2	105
Kang et al[6], 2014	South Korea	Multi	317/34	36.8 ± 12.4	5.7 ± 3.3	98 (27.9)	> 6	9	3162
Estrella et al[7], 2014	United States	Single	54/10	33 (9-62)	5 (1.4-20)	49 (76.6)	76 (2-203)	10	533
Yu et al[31], 2015	China	Multi	93/4	31.2 (16-57)	5.9 (1.5-14)	16 (16.5)	70.2 (3.5-221.5)	3	96
Zhang et al[32], 2015	China	Single	56/6	26 (8-66)	7.2 (3-15)	3 (4.8)	46 (2-135)	0	62
Yang et al[8], 2016	China	Single	58/13	31 (12-64)	5 (1-13)	13 (18.3)	45 (3-118)	3	70
Irtan et al[33], 2016	France	Multi	41/10	13.1 (8.7-17.9)	7 (2-12)	22 (43.1)	65 (0.3-221)	7	51
Marchegiani et al[34], 2016	Italy/United States	Multi	113/18	33 (7-68)	4 (0.7-20)	16 (12.2)	62 (12-304)	2	1054
Xu et al[35], 2017	China	Single	93/28	33.7 (11-68)	5 (1-13)	35 (28.9)	42.7 (6-97)	3	1005
Song et al[36], 2017	China	Single	46/7	35.4 (14-67)	6.4 (2-14)	10 (18.9)	48 (3-123)	2	456
Lubezky et al[37], 2017	Israel	Single	29/3	28.4 ± 12.2	5.9 (0.9-14)	13 (40.6)	49.2 (1-228)	4	31

Note: We included data from the latest or most complete study in the case of duplicate reports on overlapping patients from the same institutions;

¹Three patients died of SPTP, and four patients died of other causes;

²317 patients with more than 6 mo follow-up were reported for evaluation of oncologic outcome;

³Follow-up information was available for 59 patients;

⁴Follow-up information was available for 105 patients;

⁵Follow-up information was available for 103 patients;

⁶Follow-up information was available for 48 patients. F: Female; M: Male; R/M: Recurrence and/or metastasis.